DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

INSM·Insmed Incorporated

$.
-. (-.%)
After Hours
High
$118.94
Open
$118.20
Market Cap
25.63B
52W High
$212.75
Low
$112.79
P. Close
$115.55
P/E
-
52W Low
$90.39
Fwd P/E
974.82
DailyIQ Est.
$209.90
Technical Score (1D)
59
BUY
News Sentiment
51
MIXED
Insmed’s CEO William Lewis sold 10,699 shares on July 9, 2026, a transaction worth $1.26 million disclosed in a recent SEC filing. The sale increases the number of shares available to trade, potentially tightening the supply‑demand balance for the next trading week. Because insider sales can signal management’s view on the company’s valuation, the move may prompt investors to reassess the stock’s intrinsic value and liquidity profile. Over the next 1–10 trading days, the market may react to the perceived shift in insider confidence, leading to a period of heightened volatility as traders weigh the sale against the company’s fundamentals. Traders should monitor the volume and price action around the announcement to gauge whether the market interprets the sale as a bearish signal or simply a routine liquidity event. Additionally, watch for any subsequent corporate disclosures that could clarify the CEO’s rationale, such as a planned capital raise or a strategic shift. If the company issues a statement explaining the sale as part of a broader financial strategy, it could mitigate negative sentiment. Conversely, if no explanation follows, the market may lean toward a negative interpretation, increasing the risk of a short‑term decline. Finally, keep an eye on the broader biotech sector’s sentiment, as insider activity in one firm can influence sentiment across the sector in the short term.
Earnings Summary
Insmed Incorporated, a biopharmaceutical company focused on rare and serious diseases, markets its flagship ARIKAYCE for refractory nontuberculous mycobacterial lung infections and advances a combination therapy for mycobacterium avium complex, positioning it within the healthcare biotechnology sector. In its latest reporting, Insmed reported Q4 2025 earnings per share of –$1.54 versus an estimate of –$1.13, a miss, while revenue of $263.84 million beat the estimate of $226.34 million, reflecting a significant top‑line gain despite continued net losses; the preceding quarter, Q4 2024, saw EPS of –$1.32 versus –$1.16 and revenue of $104.44 million, indicating a dramatic revenue increase year‑over‑year but persistent negative earnings. Historically, Insmed’s earnings have remained negative, yet the company has demonstrated a consistent revenue expansion, with Q4 2025 revenue surpassing Q4 2024 by over 150 %, and the company’s guidance for Q2 2026 projects revenue of $397.34 million, suggesting continued growth momentum. Recent news highlights a senior leadership appointment in the Global Respiratory division, the removal from NASDAQ 110, and a rating upgrade to Overweight with a $235 target, all of which signal renewed analyst confidence and may influence short‑term sentiment; the upcoming Phase 3b readout of the TPIP inhaled PAH therapy is a key catalyst that could reshape the company’s commercial prospects. Investors should watch for the TPIP Phase 3b data release, the U.S. launch timing of brensocatib, and any updates on the company’s cash position and R&D spend, as these factors will likely determine Insmed’s near‑term earnings trajectory and valuation dynamics.

EPS

EstBeatMiss
$-1.66$-1.40$-1.14$-0.88$-0.61Q4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$-0.73 - -
Q4'25$-1.13$-1.54-36.4%
Q4'24$-1.16$-1.32-13.3%

Revenue

EstBeatMiss
$61M$156M$251M$346M$441MQ4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$397M - -
Q4'25$226M$264M+16.6%
Q4'24 - $104M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

INSM Stock Snapshot

INSM is currently trading at $115.10, giving Insmed Incorporated a market cap of 25.63B. Today's range spans $112.79–$118.94, with shares opening at $118.20 and moving down $0.45 (0.4%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 51/100.

Over the past year INSM has traded between $90.39 and $212.75 - the current price is +27.3% off the 52-week low and -45.9% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $197.05 (range $140.00–$243.00), implying upside of +71.2%.

A HOLD read (59/100) for INSM at $115.10 (in the lower half of its 52-week range) with neutral sentiment (51/100) tells the story of a large-cap Healthcare stock between identifiable trends. The 25.63B market cap keeps institutional interest alive; the 52-week range of $90.39–$212.75 keeps the trade interesting. HOLD signals here aren't an endpoint - they're a setup phase waiting for the right trigger.

The 52-week range of $90.39–$212.75 for INSM provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $115.10 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 59/100 and neutral news backdrop (51/100) don't break the tie yet, but they narrow the probability distribution toward the upside.